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ing multiple academic programs. Using ASRS-v1.1 symptom cut-off threshold, a 
prevalence rate of ADHD symptoms ranging from 21.2% to 66.2% (indicating likeli-
hood and immense likelihood of ADHD respectively) was observed for the general 
student sample. Only 3.4% of the participants had been previously diagnosed with 
ADHD. The prevalence of self-reported ADHD symptoms was higher in the age group 
of 18-23 years (81.3%) and was greater in females (53.1%). A majority of students 
had the inattentive type of symptomatology (72.72%). With regard to different 
disciplines, prevalence rates ranged from 49% (pharmacy school) to 5.9% (school 
of education). More undergraduate students reported AADHD symptoms (70.9%) 
compared to graduate students (28.4%). Students in healthcare discipline reported 
greater ADHD symptomatology (54.6%) compared to students in non-healthcare 
fields. CONCLUSIONS: Symptoms of AADHD appear to be more prevalent in stu-
dent populations than documented evidence would suggest. Among many that are 
affected, most are either unaware of the condition or undiagnosed. These findings 
have implications for students’ overall health and academic performance.
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OBJECTIVES: Given considerable variability in treatment response and medication 
side effects across individual patients using antipsychotics, customizing treatment 
to the needs of each individual is key to improving patient outcomes. This study 
examined the degree to which psychiatrists were diversified vs. concentrated in 
their choice of antipsychotic medication and identified factors associated with 
their prescribing. METHODS: Using 2011 data from Pennsylvania’s Medicaid we 
identified psychiatrists who regularly prescribed antipsychotics (defined as ≥ 10 
nonelderly patients). Using prescriber ID we linked claims data, from which we 
obtained information on patient characteristics and psychiatrist prescribing behav-
ior, to demographic information on psychiatrists from the AMA Masterfile, and to 
information on organizational affiliations from IMS Health’s HCOS TM database. 
We used three measures of antipsychotic prescribing concentration: Herfindahl 
index (HHI), share of most preferred ingredient, and number of ingredients. We 
used multiple membership linear mixed models to evaluate the degree of con-
centration for antipsychotic prescribing. Predictors included patient-, physician-, 
and organization-level factors. RESULTS: The analytic cohort included 764 psychia-
trists treating 65,256 patients. Psychiatrists prescribed several ingredients (mean: 
9); however, prescribing behavior was relatively concentrated (mean HHI: 2,603; 
share of most preferred ingredient: 37.8%), with wide variation across psychiatrists 
(range HHI: 1,088-7,270; share of most preferred ingredient: 16.4%-84.7%; number 
of ingredients: 2-17). Having a higher share of SSI-eligible patients, patients with 
serious mental illnesses, non-Hispanic whites, and older patients was associated 
with less concentrated prescribing although effects were relatively small (all p< .05). 
Female psychiatrists had more concentrated prescribing than that of their male 
counterparts (p< .10). Psychiatrists affiliated with behavioral health organizations 
had more diversified antipsychotic prescribing. CONCLUSIONS: Antipsychotic pre-
scribing behavior in a large state Medicaid program was relatively concentrated 
and varied substantially across psychiatrists. Some psychiatrists treating Medicaid 
enrollees with antipsychotics may be limited in their ability to tailor treatment to 
individual patient needs and preferences.
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OBJECTIVES: Kentucky House Bill 1 (HB1) was enacted in July 2012 to address pre-
scription drug abuse and diversion. This legislation included stronger pain clinic 
regulations, mandatory prescriber registration with Kentucky’s prescription drug 
monitoring program (PDMP) and mandatory use of PDMP data prior to issuing a 
new controlled substance prescription. The purpose of this study was to assess 
the impact of HB1 on the concurrent prescribing of three controlled substances: 
an opioid (hydrocodone or oxycodone), alprazolam, and carisoprodol (OAC). This 
combination has been identified as a signal for misuse and diversion. METHODS: 
De-identified PDMP data from July 2009 through June 2013 was analyzed to deter-
mine the number of patients who concurrently received prescriptions for OAC. 
Concurrent was defined as receiving prescriptions for each OAC component within 
30 days. 12-month OAC totals were compared for each fiscal year (defined in KY as 
July 1 – June 30). Fiscal years were chosen for analysis based on the date of imple-
mentation of legislation (July 2012). Differences in mean number of patients receiv-
ing concurrent OAC prescriptions were analyzed using two-tailed t-tests for fiscal 
years pre and post legislation. RESULTS: The number of patients receiving concur-
rent OAC prescriptions for OAC during the study period were 22,423 (FY2010), 25,465 
(FY2011), 22,795 (FY2012), and 15,983 (FY2013). The number of patients receiving 
concurrent OAC prescriptions was significantly lower (P< 0.001) in FY2013 relative 
to FY2012. CONCLUSIONS: Implementation of Kentucky House Bill 1 was associ-
ated with a 29.9% decrease in the concurrent prescribing of a combination of CS 
commonly associated with misuse and diversion. Further studies to differentiate 
the relative impact of pain clinic regulations from the impact of mandatory regis-
tration and use legislation are warranted to determine the effectiveness of these 
approaches in curbing the abuse and diversion of prescription drugs.
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than low volume prescribers. Primary care providers were substantially less likely 
than psychiatrists to prescribe clozapine (OR = 0.55, p< 0.01) but just as likely to 
antipsychotic polypharmacy. CONCLUSIONS: Antipsychotic polypharmacy is used 
as much as clozapine in the care of Medicaid beneficiaries with schizophrenia, but 
many prescribers only use the former. Clinical and policy initiatives are needed to 
improve providers’ knowledge of clozapine and increase its use while decreasing 
use of antipsychotic polypharmacy.
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OBJECTIVES: To examine prevalence rates and co-relates of non-medical use of 
prescription stimulants for attention-deficit-hyperactivity disorder (ADHD) in a uni-
versity student population with respect to student demographics and academic 
characteristics. METHODS: A cross-sectional research design, utilizing a conveni-
ence sampling and self-administered paper and pencil questionnaire technique, 
was adopted. The survey consisted of a screening tool to measure symptoms of 
Adult ADHD Self-Report Scale (ASRS-v1.1) in conjunction with items to measure the 
extent of self-reported prescription drug abuse among students. The use of prescrip-
tion stimulants was profiled for students representing different schools and aca-
demic programs and reasons for the nonmedical use were documented. RESULTS: A 
sample of 638 completed surveys (response rate= 98.15%) was obtained with data on 
unauthorized use of prescription drugs. About 8.62% (N= 55) of the sample reported 
a current and past use of drugs such as Adderall, Ritalin, Dexedrine, Concerta, Cylert 
at least once. Of these, 76.9% used the drugs non-medically for enhancing academic 
performance and 23.1% used them for increasing alertness. The illicit drug usage 
was higher in the age group 18-23 years (87.2%) and was greater for males (64.1%). 
Overall, students from pharmacy school reported highest abuse (46.2%), followed 
by law school (20.5%), school of professional studies (12.8%) and business school 
(10.3%). Generally, undergraduate students reported greater use of prescription 
stimulants (69.2%) compared to graduate students (30.8%). A majority (66.7%) of 
the students were also attending professional degree programs. CONCLUSIONS: 
The current campus estimates are mostly in line with the national statistics (4.1% 
to 10.8%, according to the Center for Lawful Access and Abuse Deterrence, CLAAD, 
2013). Misuse and abuse of prescription stimulants among students is a growing 
problem and largely remains unaddressed. Development of campus educational 
tools to prevent sharing of prescription drugs and guidelines to recognize early 
warning signs to curb abuse are necessary.
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OBJECTIVES: Doctor shopping is a principle method of obtaining controlled sub-
stances (CS) for misuse and is an indicator of escalating drug abuse and fatal over-
dose. Currently, numerical thresholds are used to identify doctor shoppers, but 
a lack of consensus on criteria has led to wide variations in estimated rates. The 
goal of this study was to investigate the feasibility of using social network analy-
sis (SNA) to improve the specification and predictive validity of doctor shopping 
indicators. METHODS: i3 Innovus InVision™ data for the year 2009 was used to 
identify doctor shoppers using the 4 CS (opioid or benzodiazepine) prescriptions 
+ 4 pharmacies criterion. A network of physicians was created using indirect ties 
defined by co-prescription to the same doctor shopping patient. A visualization of 
the clinician network was created to assess clustering, and bivariate analyses were 
conducted to assess the relationship between physician centrality, or number of ties 
to other prescribers through a common doctor shopping patient, in the co-prescrib-
ing network and average characteristics of a physician’s patients. RESULTS: A total 
of 89,297 clinicians prescribed an opioid or benzodiazepine to at least one doctor 
shopper. The mean degree of centrality was 23.15 (SD 61.48 and ranged from 0-995). 
Physician degree centrality is positively correlated with patients’ average number 
of pharmacies (r= .28, p< .001), number of prescriptions (r= 0.21, p< .001), number of 
MPEs (r= 0.43; p< .001), and number of repeated visits to the same prescriber (r= 0.13, 
p< .001). The network visualization map revealed a large network of 7,288 doctors 
tied by 45,181 co-prescribing relationships. CONCLUSIONS: The results of this study 
confirm the feasibility of using SNA to identify doctor shoppers. Further studies 
using two-mode SNA are warranted to improve the specification and predictive 
validity of doctor shopping indicators and to determine the patient, clinician, and 
point-of-service characteristics associated with doctor shopping behavior.
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OBJECTIVES: To estimate prevalence of Adult ADHD (AADHD) symptoms among uni-
versity-based students across multiple academic disciplines. METHODS: A cross-
sectional research design, utilizing convenience sampling and self-administered 
paper and pencil questionnaire technique, was adopted. Adult students (> 18 years) 
were recruited from a university campus in New York City area. AADHD Self-Report 
Scale- v1.1 (ASRS v1.1), a pre-validated screening instrument, was used to assess 
performance along inattention, hyperactivity/impulsivity and combined symptom 
sets of adult ADHD. A score of 17 or more on an ASRS v1.1 scale between 0 and 72 
indicates the likelihood of ADHD, whereas a score of 24 or more indicates immense 
likelihood of ADHD. Individual component scores of ASRS were compared for stu-
dents from six different schools and programs within the university. RESULTS: 
The final sample consisted of 638 students from six different schools represent-
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able in this large Medicaid cohort. Patients who used buprenorphine persistently 
for 12 months had lower risk of all-cause hospitalizations and ED visits than those 
experiencing early discontinuation.
PMH80
PrescriPTion PaTTerns following firsT-line second-generaTion 
anTiPsycHoTics for PaTienTs wiTH scHizoPHrenia in JaPan: an 
insurance claiMs daTabase analysis
Jamotte A.1, Onishi Y.2, Clay E.1, Aballea S.1
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical K.K., Tokyo, Japan
OBJECTIVES: Clinical guidelines for schizophrenia recommend monotherapy of 
second-generation antipsychotics (SGAs) for treating patients suffering from schizo-
phrenia, but do not address the issue of how to treat patients with inadequate first-
line treatment. The aim of this study is to describe real-word prescription patterns 
for patients suffering from schizophrenia in Japan. METHODS: Using data from the 
Japan Medical Data Center (JMDC) database, a retrospective longitudinal cohort study 
was conducted, including adults aged from 18 to 65 years with a first prescription of 
antipsychotic (index date) between January 2009 and September 2013, and diagnosed 
with schizophrenia around index date. The treatments prescribed in first and second 
lines were described and treatment duration was estimated using the Kaplan-Meier 
method. Proportions of patients receiving an add-on treatment, switching or not 
treated after discontinuation of first-line treatment were estimated. RESULTS: 1,674 
patients were included. Mean age of the population was 35.4±11.2 years at index 
date and 54.5% were females. 82% of these patients received SGA monotherapy as 
first-line therapy. Among this subgroup, the most frequently prescribed drugs were: 
olanzapine (27.1%), aripiprazole (27.0%), risperidone (22.1%) and quetiapine (16.3%). 
64% of patients reached end of first-line treatment within 6 months, of whom 26.6% 
had a switch, 11.6% had an augmentation and 61.8% stopped treatment. The median 
duration of first-line treatment was 3 months. Most frequently prescribed therapies 
in second line were aripiprazole (23.2%), olanzapine (22.5%), quetiapine (13.7%) and 
risperidone (9.1%), and 6.3% were antipsychotic combinations. CONCLUSIONS: SGA 
monotherapy was frequently prescribed as first-line treatment, consistently with 
clinical guidelines. However the duration of first-line therapy is short and the high 
proportion of patients without treatment may be a cause for concern.
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OBJECTIVES: To examine the risk of hospitalization due to cardiovascular events 
associated with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors, compared to 
other anti-diabetic agents, among diabetic patients. METHODS: Patients age > 18 
years and taking diabetes medication were identified in the IMS Lifelink Plus® 
database for the years 2006-2013. Cardiovascular events were defined as inpatient 
discharge diagnosis of heart failure, stroke and coronary heart disease occurring at 
least 30 days after initiation of therapy. Patients were continuously enrolled for 6 
months prior and 24 months post the date of first antidiabetic prescription (‘index-
date’). Patients with cardiovascular event in 6-month pre-index period were excluded. 
Patients were followed for 24 months post index-date. Patients with at-least 30 days 
of DPP-4 inhibitors as their starting therapy were identified as DPP-4 inhibitors users, 
while patients with at-least 30 days of any other anti-diabetic therapy and no DPP-4 
inhibitors in the 24-month follow-up period were identified as other anti-diabetic 
users. Unadjusted and adjusted logistic regression models were employed to esti-
mate the risk of cardiovascular-related hospitalizations for those on DPP-4 inhibi-
tors, compared with those on other antidiabetic agents. The model was adjusted for 
demographics, comorbidities, and region of residence. RESULTS: The final sample 
consisted of 45,767 patients with mean age of 50.71 years and 55.15 % females. Of 
these, 1973 patients had DPP-4 inhibitors while 43,794 had other anti-diabetic therapy. 
At baseline 2.43% patients had hypertension, 36.06% had dyslipidemia and 28.63% 
had valve disorder. Patients taking DPP-4 inhibitors had an increased risk for having 
a cardiovascular event as compared with those on other anti-diabetic agents (unad-
justed odds ratio:1.524, 95% confidence interval [CI]:1.131-2.056; adjusted odds ratio: 
1.331, 95% CI: 0.985-1.799). CONCLUSIONS: DPP4 inhibitors may increase the risk of 
cardiovascular events as compared to other anti-diabetic agents, which warrants 
close monitoring of diabetic patients on DPP-4 inhibitors.
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OBJECTIVES: To examine the incidence of different types of adverse drug 
reactions(ADR) in a group of drug treated hypertensive patients. METHODS: This 
is a cross sectional study conducted in collaboration with Department of Internal 
Medicine, College of Medical Sciences and Teaching Hospital, Bharatpur, Chitwan 
during the period of three months (1st July to 30th September 2014). The patients 
attending the outpatient department of Cardiology and under antihypertensive 
drugs therapy were taken as sample. RESULTS: Among the total 100 patients stud-
ied, the mean age was 58.56 ± 12.83 years. Males contributed to 59 and females 41 
OBJECTIVES: This study aims to explore physician care-providing behavior in 
treating children and adolescents with Attention-deficit/hyperactivity disorder 
(ADHD). METHODS: The study was conducted using the GE electronic medical 
records (GE-EMR) 1995-2010. The cohort consisted of all children and adolescents 
(age≤ 18 years), who were prescribed either stimulants or atomoxetine hydrochloride 
and had at least two physician visits. Incident ADHD cases, defined as those who 
have not been diagnosed with ADHD or received ADHD prescription in the last 6 
months, were followed for a period of 12 months to observe their physician care-
providing behavior. RESULTS: Approximately 5% of children in the GE-EMR were 
diagnosed with ADHD. 74% of the cases were identified by primary care physicians 
(PCPs), 5% by a mental health specialist, and the remaining cases had missing pro-
vider specialties. 52% (N= 101,516) of ADHD cases were prescribed pharmacotherapy 
immediately following the first ADHD diagnosis, while 43% (N= 35,069) had delayed 
prescriptions with median time to treatment of 55 days (IQR: (21-171 days)). ADHD 
cases first identified by PCPs were more likely to receive immediate pharmaco-
therapy than those identified by mental health specialists (58% vs 41%, P= < 0.0001). 
The majority of the children who received pharmacotherapy were prescribed stimu-
lants (89%), about 10% were prescribed atomoxetine and less than 1% were on a 
combination of the two. The most commonly prescribed concurrent non-ADHD 
medications were antidepressants (11%) and atypical antipsychotics (4.6%). During 
the one year follow-up, children with ADHD had an average of six office visits with 
the first follow-up visit at an average of 51 days after treatment initiation. Only 
0.39% (N= 318) of children received concurrent psychotherapy. CONCLUSIONS: As 
compared to mental health specialists, PCPs are more likely to prescribe pharmaco-
therapy immediately after the ADHD cases were identified. Medication concurrent 
psychotherapy is low in patients seen by either PCPs or mental health specialists.
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OBJECTIVES: Little evidence exists to support the increasing concurrent use of mul-
tiple antipsychotics (APs) among children. Case reports suggest that use of multiple 
APs could lead to an increased risk of delirium, serious behavioral changes, cardiac 
arrhythmias, and death. In 2013, the National Collaborative for Innovation in Quality 
Measurement (NCINQ) proposed a quality measure of concurrent use of multiple 
(2+) APs among children for use in Medicaid and CHIP programs. The Pharmacy 
Quality Alliance (PQA) has been working on a similar measure using 3+ APs. The 
objectives were to analyze the performance in the Mississippi Medicaid program on 
both the 2+ and 3+ proposed quality measures. METHODS: A retrospective analysis 
was conducted using Mississippi Medicaid data for July 2013 through June 2014. For 
both measures the denominator contained beneficiaries ages 0 to 21 as of June 2014, 
who were continuously enrolled 3+ months and were on any AP for at least 90 days. 
The numerators contained those beneficiaries who were concurrently on 2+ APs or 
3+ APs for a period of at least 90 days during the measurement year. RESULTS: The 
denominator included 4,435 children who were on at least 1 AP. About 464 (10.5%) 
and 159 (3.6%) beneficiaries were concurrently on 2+ or 3+ APs respectively. The 
performance rates on the two measures did not significantly differ for the fee-for-
service or two managed care plans. Also, the performance rates on the measures 
decreased with an increase in beneficiary age. These results also were consistent 
across the three health plans. CONCLUSIONS: There is considerable debate about 
the rate of appropriate concurrent use of 2+ APs in this population. However, there is 
no clinical support for concurrent use of 3+ APs. Although the percentage of children 
concurrently taking 3+ APs is small, possible drug utilization management actions 
are needed to further reduce this occurrence.
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OBJECTIVES: Buprenorphine is an effective treatment for opioid use disorders. 
However, uncertainty about optimal duration of buprenorphine treatment may 
lead to substantial variation in provider decision-making, and patient outcomes. In 
response to the high cost of treatment, some payers have placed limits on treatment 
duration although little is known about the impact of these limits. We used group-
based trajectory models to identify distinct trajectories of buprenorphine use based 
on prescription refills, and examined emergency department (ED) and inpatient use 
associated with these trajectories in a large state Medicaid program. METHODS: 
We analyzed data from a retrospective cohort study of 10,945 adults (18-64 years) 
Pennsylvania Medicaid enrollees initiating a new episode of buprenorphine treat-
ment between 2007-2011. We used group-based trajectory models to identify tra-
jectories in the 12 months following buprenorphine initiation. Multivariate Cox 
proportional hazard models were used to examine the association between tra-
jectories and time to first all-cause hospitalization and first emergency depart-
ment (ED) visit in the following year. RESULTS: Six trajectories of buprenorphine 
treatment were identified: 4 groups discontinued buprenorphine (24.9% discon-
tinued < 3 months, 18.7% at 3-5 months, 12.4% at 5-8 months, 13.3% > 8 months); 
9.5% refilled intermittently; and 21.2% refilled persistently for 12 months. Factors 
associated with treatment discontinuation were minority race, having history of 
frequent ED visits and hospitalizations, and comorbid psychoses. After adjusting 
for sociodemographics, health status, and provider-level covariates, patients who 
refilled persistently had a 20% lower risk of all-cause hospitalizations (hazard ratio 
[HR]= 0.80, 95% CI, 0.68-0.94) and 15% lower risk of an ED visit (HR= 0.85, 95% CI, 
0.77-0.94) in the subsequent year, compared to those discontinuing between 3-5 
months. CONCLUSIONS: Buprenorphine treatment trajectories were highly vari-
